NYSE: PHGKoninklijke Philips Nv Stock
$25.35+0.32 (+1.28%)
Updated Apr 30, 2025
PHG Price
$25.35
Fair Value Price
N/A
Market Cap
$23.45B
52 Week Low
$21.48
52 Week High
$32.91
P/E
-32.13x
P/B
1.86x
P/S
1.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.97B
Earnings
-$731.25M
Gross Margin
43.1%
Operating Margin
3.6%
Profit Margin
-3.9%
Debt to Equity
1.41
Operating Cash Flow
$2B
Beta
0.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PHG Overview
Koninklijke Philips N.V. develops and manufactures medical systems (diagnostic imaging, enterprise diagnostic informatics, image-guided therapy, ultrasound, monitoring and analytics, sleep and respiratory care, population health management, and connected care informatics and therapeutic care products). It also offers baby care products (baby bottles, sterilizers, etc.), personal care products (brush heads, shavers, groomers, trimmers, skin care, hair care and hair removal), oral healthcare products (power toothbrushes), and consumer electronics products. Koninklijke Philips was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PHG
Ranked#32 of 108
Ranked#32 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.31 | A | |
| $23.03 | A | |
| $14.12 | A |
Be the first to know about important PHG news, forecast changes, insider trades & much more!
PHG News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHG scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHG is good value based on its book value relative to its share price (1.86x), compared to the US Medical Devices industry average (3.94x)
P/B vs Industry Valuation
PHG is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more PHG due diligence checks available for Premium users.
Valuation
PHG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-32.13x
Industry
37.39x
Market
29.18x
PHG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.86x
Industry
3.94x
PHG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHG's financial health
Profit margin
Revenue
$18.8B
Net Income
-$731.3M
Profit Margin
-3.9%
PHG's Earnings (EBIT) of $682.11M... subscribe to Premium to read more.
Interest Coverage Financials
PHG's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$30.2B
Liabilities
$17.6B
Debt to equity
1.41
PHG's short-term assets ($10.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHG's short-term assets ($10.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHG's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PHG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.6B
Investing
-$596.9M
Financing
-$516.7M
PHG's operating cash flow ($1.65B)... subscribe to Premium to read more.
Debt Coverage Financials
PHG vs Medical Device Stocks
Koninklijke Philips Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.